SEC Form 4 · accession 0001209191-16-155518
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maninder Hora
Officer — SVP Pharma Dev & Mfg Ops
Period of report
Dec 13, 2016
Accepted (ET)
Dec 15, 2016 · 8:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 13, 2016 | A | 15,000 | $0.00 | A | 65,843 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3 | $12.24 | Dec 13, 2016 | A | 37,500 | A | — | Dec 12, 2024 | Common Stock | 37,500 | 37,500 | D |
Explanation of responses
- F1This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in equal quarterly installments based on continued service.
- F2This number includes 5,500 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c).
- F3This stock option vests over four years in equal monthly installments based on continued service.